Cargando…
Stem Cells and Cancer
Significance of Stem Cells to Tumor Development Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies,...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2009.
|
| Edición: | 1st ed. 2009. |
| Colección: | Cancer Drug Discovery and Development,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-60327-933-8 | ||
| 003 | DE-He213 | ||
| 005 | 20220114144001.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2009 xxu| s |||| 0|eng d | ||
| 020 | |a 9781603279338 |9 978-1-60327-933-8 | ||
| 024 | 7 | |a 10.1007/978-1-60327-933-8 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Stem Cells and Cancer |h [electronic resource] / |c edited by Rebecca G. Bagley, Beverly A. Teicher. |
| 250 | |a 1st ed. 2009. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2009. | |
| 300 | |a XVI, 346 p. 62 illus., 16 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 505 | 0 | |a TO CANCER STEM CELLS -- The Cancer Stem Cell Hypothesis -- Tumor Stem Cells and Malignant Cells, One and the Same -- THE STEM CELL NICHE -- Mesenchymal Stem Cells in Tumor Stroma -- MOLECULAR PATHWAYS AND GENE EXPRESSION -- Wnt Signaling in Cancer: From Embryogenesis to Stem Cell Self-Renewal -- PTEN in Hematopoietic and Intestinal Stem Cells and Cancer -- Transcription Factors in Cancer Stem Cells of the Hematopoietic Lineage -- Stem Cell Chromatin Patterns and DNA Hypermethylation -- Plasticity Underlying Multipotent Tumor Stem Cells -- CANCER STEM CELLS IN SOLID TUMORS -- Glioma Stem Cells in the Context of Oncogenesis -- Mouse Mammary Tumor Virus: Stem Cells and Mammary Cancer -- Tumor Dormancy, Metastasis, and Cancer Stem Cells -- Cancer Stem Cells: Gastrointestinal Cancers -- Cancer Stem Cells: Hepatocellular Carcinoma -- Cancer Stem Cells: Lung Cancer -- Cancer Stem Cells: Pancreatic Cancer -- Prostate Stem Cells and Cancer in Animals -- Prostate Cancer Stem/Progenitor Cells -- Adult Prostate Epithelium Renewal, Stem Cells and Cancer -- Stem Cells, Angiogenesis, and Neurogenesis in Tumors -- TARGETING CANCER STEM CELLS WITH THERAPY -- Implications of Cancer Stem Cells for Cancer Therapy -- Targeting Leukemic Stem Cells -- Targeting Brain Cancer Stem Cells in the Clinic -- Critical Roles of Tumorigenic and Migrating Cancer Stem/Progenitor Cells in Cancer Progression and their Therapeutic Implications -- Therapeutic Index and the Cancer Stem Cell Paradigm. | |
| 520 | |a Significance of Stem Cells to Tumor Development Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease. This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize 'side populations.' Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic versus epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. Stem Cells and Cancer represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation for many years to come. Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies, gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation. Dr. Beverly A. Teicher is Vice President of Oncology Research at Genzyme Corporation. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. Dr. Teicher is an active member of the international scientific community having authored or co-authored more than 400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Pharmacology. |
| 700 | 1 | |a Bagley, Rebecca G. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Teicher, Beverly A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781603279369 |
| 776 | 0 | 8 | |i Printed edition: |z 9781617379208 |
| 776 | 0 | 8 | |i Printed edition: |z 9781603279321 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-60327-933-8 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||